register

News & Trends - Pharmaceuticals

PBS Schedule review must retain access to medicines for palliative care patients

Health Industry Hub | November 5, 2020 |

Pharma News: A decision to review the Pharmaceutical Benefits Scheme (PBS) Palliative Care Schedule has been welcomed by Palliative Care Australia (PCA) and the Royal College of General Practitioners (RACGP) and described as an important step in ensuring palliative care patients are provided flexible access to the medicines they need.

The announcement by the Pharmaceutical Benefits Advisory Committee (PBAC) follows submissions by PCA, the RACGP and others, concerning the retention, deletion, and amendment of items on the Palliative Care
Schedule.

In a statement, PBAC acknowledged that aligning the Palliative Care Schedule opioid listings with the recent changes to the General PBS Schedule would support the “appropriate prescribing and use of opioids” while continuing its support of the quality use of opioids without impact to the appropriate supply of opioids to palliative patients.

Opioid medicines are an essential element of pain and symptom management strategies, when used responsibly by health professionals, to support palliative care patients.

PCA Board Chair Professor Meera Agar said governments and regulators generally acknowledge this reality, but it is vital to ensure the rules and restrictions surrounding opioids always reflect the current evidence-based practices.

She believes the review is a step in the right direction to provide better pain management for non-cancer palliative care patients.

“All Australians receiving palliative care must be able to access necessary opioids to manage and prevent suffering from uncontrolled pain and other symptoms. It’s therefore vital that we increase the understanding of appropriate use of opioids within the Australian palliative care context,” Prof Agar said.

Acting RACGP President Associate Professor Ayman Shenouda said that the decision by Pharmaceutical Benefits Advisory Committee was a positive step forward for patient care.

“As a GP I have treated many patients receiving care at the end of their life, we must do all we can to help them live their last moments with as much dignity and comfort as possible.

“A key component of that is ensuring that these patients do not incur high costs of care due to being denied PBS subsidies or access to the recommended medicines. It is also vital that they have access to the right types of opioids when they need them.

“When considering the PBS’s Palliative Care Schedule, we must think carefully about how to relieve distressing symptoms in patients in a variety of challenging circumstances. That includes those who have difficulty swallowing, people in remote Indigenous communities or patients intolerant to some opioids like morphine.

“It is most welcome news that PBAC has acknowledged that aligning the opioid listings with the recent changes to the PBS Schedule would support the appropriate scheduling and use of these drugs.”

PCA CEO Rohan Greenland said Palliative Care Australia has the expertise to advise governments on the review of the PBS Palliative Care Schedule.

“Palliative Care Australia has released a position statement on sustainable access to prescription opioids in palliative care last year, which has been endorsed by several palliative care and healthcare organisations. We look forward to continuing to work closely with PBAC and contributing to a successful review of the PBS Palliative Care Schedule,” Mr Greenland said.


Human Resources

Medtronic HR Director deep dives into shifting workplaces and leadership trends: International HR Day

Medtronic HR Director deep dives into shifting workplaces and leadership trends: International HR Day

Health Industry Hub | May 20, 2024 |

People & Culture: Coinciding with International HR Day, Karen Newell, Senior HR Director for ANZ at Medtronic, joined Health Industry […]

More


News & Trends - MedTech & Diagnostics

Aussie medtech reveals new data on next-gen pulsed field ablation system for atrial fibrillation

Aussie medtech reveals new data on next-gen pulsed field ablation system for atrial fibrillation

Health Industry Hub | May 20, 2024 |

MedTech & Diagnostics News: An Australian-based medtech company announced promising results from the first-in-human study for its pulsed field ablation […]

More


News & Trends - MedTech & Diagnostics

Federal budget delivers 'mixed news' for radiologists

Federal budget delivers ‘mixed news’ for radiologists

Health Industry Hub | May 20, 2024 |

MedTech & Diagnostics News: The Royal College of Australian and New Zealand Radiologists (RANZCR) and the Interventional Radiology Society of […]

More


News & Trends - Pharmaceuticals

AstraZeneca, BMS and Noxopharm address findings of inquiry report into rare cancers

AstraZeneca, BMS and Noxopharm address findings of inquiry report into rare cancers

Health Industry Hub | May 20, 2024 |

Pharma News: The Senate Community Affairs References Committee has released its inquiry report into Equitable access to diagnosis and treatment […]

More


This content is copyright protected. Please subscribe to gain access.